A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease (SERENITY)
The purpose of this study is to evaluate the safety and effectiveness of the study drug LY3074828 in participants with active Crohn's Disease.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participant must have active Crohn's Disease (i.e., currently having a flare, or experiencing symptoms)
Participant must have had inadequate response or failure to tolerate at least one of the following: amino salicylates; budesonide; systemic corticosteroids; immunosuppressants (eg, azathioprine, 6-mercaptopurine, or methotrexate); or prior exposure to biologics for the treatment of Crohn's Disease
Participants Must Not:
Participant must not have complications of Crohn's Disease such as strictures, stenosis, or any other manifestation for which surgery might be indicated
Participant must not have a diagnosis of any condition affecting the digestive tract, such as ulcerative colitis, indeterminate colitis, fistulizing disease, abdominal or perianal abscess, adenomatous colonic polyps not excised, colonic mucosal dysplasia, and short bowel syndrome
Participant must not have had any kind of bowel resection, diversion, or placement of a stoma within 6 months or any other intra-abdominal surgery within 3 months prior to screening
Lilly Trial Alerts
You will complete the questionnaire on another website.YesNo